About General Oncology
General Oncology is a private company based in Newton, Massachusetts. It has reported $15,684,607 raised in two offerings on Form D since July 2019. Its chief executive is Jeffrey Glazier.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | Apr 23, 2026 | $4,805,299fully sold | 37 | $129K | Options, Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.Rule 506(b) | Form D ↗ |
| Jun 25, 2019 | Jul 9, 2019amended Jul 2, 2025 | $10,879,308of $17.3M target | 43 | $253K | Equity, OptionsRule 506(b) | Form D/A ↗8 earlier filings |
| Total, two offerings | $15,684,607 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on General Oncology's Form D filed Apr 23, 2026.
Earlier filings also listed Henry Esber (director, last listed Sep 2017) and Gregg Goldstein (president and director, last listed Sep 2017).
Sources
- SECGeneral Oncology, Inc. Form D/A, filed Jul 2, 2024
- SECGeneral Oncology, Inc. Form D/A, filed Dec 21, 2023
- SECGeneral Oncology, Inc. Form D/A, filed Dec 22, 2022
- SECGeneral Oncology, Inc. Form D/A, filed Nov 10, 2022
- SECGeneral Oncology, Inc. Form D/A, filed Nov 10, 2021
- SECGeneral Oncology, Inc. Form D/A, filed Dec 23, 2020
- SECGeneral Oncology, Inc. Form D/A, filed Jul 14, 2020
- SECGeneral Oncology, Inc. Form D, filed Jul 9, 2019
- SECGeneral Oncology, Inc. filing history
- CompanyAbout General Oncology
- CompanyPrivacy policy
- CompanyChief financial officer appointment